Lipid Disorder Treatment Market By Product Type ( Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin ), By Distribution Channe ( Retail Pharmacies, Hospital Pharmacies, Online Pharmacies ), By Indication ( Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia ), Industry Trends, Estimation & Forecast, 2017 - 2025

Check Today's Best Price

$3500 Buy Now
Lipid Disorder Treatment Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.
  • Market Overview:

    Lipids are one of the major components of the body which are made up of hydrocarbons and are extensively important in the formation and functioning of living cells. They are fat like substances and reside in the form of oils, waxes and vitamins within the body. In the common term, lipids are also called as cholesterol. Lipids play a major role in the proper functioning of the body, especially the cardiovascular system, but, can be equally dangerous if not balanced in a certain ratio. Lipid disorder is one of the fastest emerging health issue in the world, among all age groups; from children to adults. The presence of improper amount of LDL-Cholestrol and Tryglycerides in the blood stream is the major cause of lipid related health problems.

    The excessive amount of bad-cholestrol can lead to cardiovascular issues such as atherosclerosis, internal blood clots, estrogen drop, loss of memory, gall stones, fatigue and even fatal heart attacks. As per WHO, nearly one-third of all the ischaemic heart diseases are caused as a result of high cholesterol. A constant rise in the occurrence of cardio-vascular diseases is the major factor which is propelling the demand for lipid disorder treatment or therapies all over the world. Moreover, changing trends, sedentary lifestyle, improper food habits and constantly increasing obesity are the major causes which are leading to the generation of lipid disorders, especially among the people under the age-group of (40-60) years. As per the Centers of Disease Control and Prevention, nearly 71 million Americans have high low-density lipoprotein (LDL). Constantly increasing awareness and government initiatives such as seminars and health checkup camps might stimulate the global lipid disorder treatment market growth in the near future.

    The report provides detailed qualitative and quantitative analysis of the Lipid Disorder Treatment Market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely type and application in each of the major regions.

    Lipid Disorder Treatment Market Segmentation

    By Product Type

    • Atorvastatin
    • Fluvastatin
    • Rosuvastatin
    • Simvastatin
    • Pravastatin
    • Other

    By Distribution Channel

    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies

    By Indication

    • Familial Combined Hyperlipidemia
    • Familial Defective Apolipoprotein B-100
    • Familial Dysbetalipoproteinemia
    • Familial Hypertriglyceridemia
    • Heterozygous Familial Hypercholesterolemia
    • Other

    By Geography

    North America
    o U.S.
    o Canada
    o Mexico

    • Europe
    o U.K.
    o France
    o Germany
    o Italy
    o Spain
    o Rest of Europe

    • Asia-Pacific
    o China
    o Japan
    o India
    o Korea
    o Rest of APAC

    • South America
    o Brazil
    o Rest of South America

    • Rest of the World
    o Middle East
    o Africa

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC desk research
    1.1.2. ERC data synthesis
    1.1.3. Data validation and market feedback
    1.1.4. ERC data sources

    CHAPTER 2. LIPID DISORDER TREATMENT MARKET OVERVIEW
    2.1. LIPID DISORDER TREATMENT MARKET INTRODUCTION
    2.2. GLOBAL LIPID DISORDER TREATMENT MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    2.2.1. Global Lipid Disorder Treatment Production (VOLUME) and Growth Rate (%), (2017-2025)
    2.3. GLOBAL LIPID DISORDER TREATMENT MARKET CAPACITY AND GROWTH RATE, 2017-2025
    2.3.1. Global Lipid Disorder Treatment Capacity (VOLUME) and Growth Rate (%), (2017-2025)
    2.4. GLOBAL LIPID DISORDER TREATMENT MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.4.1. Global Lipid Disorder Treatment Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
    2.5. GLOBAL LIPID DISORDER TREATMENT MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    2.5.1. Global Lipid Disorder Treatment Consumption (VOLUME) and Growth Rate (%), (2017-2025)
    2.6. GLOBAL LIPID DISORDER TREATMENT MARKET PRICE TREND, 2017-2025
    2.6.1. Global Lipid Disorder Treatment Market Price Trend and Growth Rate (%), (2017-2025)

    CHAPTER 3. GLOBAL LIPID DISORDER TREATMENT MARKET BY PRODUCT TYPE, 2017-2025
    3.1. ATORVASTATIN
    3.2. FLUVASTATIN
    3.3. ROSUVASTATIN
    3.4. GLOBAL LIPID DISORDER TREATMENT MARKET REVENUE BY PRODUCT TYPE, 2017-2025
    3.4.1. Global Lipid Disorder Treatment Market Revenue (Million USD) and Share (%) By Product Type, 2017-2025
    3.4.2. Atorvastatin Market Revenue and Growth Rate, 2017-2025
    3.4.3. Fluvastatin Market Revenue and Growth Rate, 2017-2025
    3.4.4. Rosuvastatin Market Revenue and Growth Rate, 2017-2025
    3.5. GLOBAL LIPID DISORDER TREATMENT MARKET PRODUCTION BY PRODUCT TYPE, 2017-2025
    3.5.1. Global Lipid Disorder Treatment Market Production (Volume) and Share (%) By Product Type, 2017-2025
    3.5.2. Atorvastatin Market Production and Growth Rate, 2017-2025
    3.5.3. Fluvastatin Market Production and Growth Rate, 2017-2025
    3.5.4. Rosuvastatin Market Production and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other product type segment.

    CHAPTER 4. GLOBAL LIPID DISORDER TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2017-2025
    4.1. RETAIL PHARMACIES
    4.2. HOSPITAL PHARMACIES
    4.3. ONLINE PHARMACIES
    4.4. GLOBAL LIPID DISORDER TREATMENT MARKET REVENUE BY DISTRIBUTION CHANNEL, 2017-2025
    4.4.1. Global Lipid Disorder Treatment Market Revenue (Million USD) and Share (%) By Distribution Channel, 2017-2025
    4.4.2. Retail Pharmacies Market Revenue and Growth Rate, 2017-2025
    4.4.3. Hospital Pharmacies Market Revenue and Growth Rate, 2017-2025
    4.4.4. Online Pharmacies Market Revenue and Growth Rate, 2017-2025
    4.5. GLOBAL LIPID DISORDER TREATMENT MARKET CONSUMPTION BY DISTRIBUTION CHANNEL, 2017-2025
    4.5.1. Global Lipid Disorder Treatment Market Consumption (Volume) and share (%) By Distribution Channel, 2017-2025
    4.5.2. Retail Pharmacies Market Consumption and Growth Rate, 2017-2025
    4.5.3. Hospital Pharmacies Market Consumption and Growth Rate, 2017-2025
    4.5.4. Online Pharmacies Market Consumption and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for indication segment.

    CHAPTER 5. GLOBAL LIPID DISORDER TREATMENT MARKET BY REGION, 2017-2025
    5.1. NORTH AMERICA
    5.1.1. U.S.
    5.1.2. Canada
    5.1.3. Mexico
    5.2. EUROPE
    5.2.1. U.K.
    5.2.2. France
    5.2.3. Germany
    5.2.4. Italy
    5.2.5. Spain
    5.2.6. Rest of Europe
    5.3. ASIA PACIFIC
    5.3.1. China
    5.3.2. Japan
    5.3.3. India
    5.3.4. Korea
    5.3.5. Rest of APAC
    5.4. SOUTH AMERICA
    5.4.1. Brazil
    5.4.2. Rest of South America
    5.5. REST OF THE WORLD
    5.5.1. Middle East
    5.5.2. Africa
    5.6. GLOBAL LIPID DISORDER TREATMENT MARKET REVENUE BY REGION, 2017-2025
    5.6.1. Global Lipid Disorder Treatment Market Revenue (Million USD) and Share (%) By Region, 2017-2025
    5.6.2. North America Market Revenue and Growth Rate, 2017-2025
    5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
    5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
    5.6.5. South America Market Revenue and Growth Rate, 2017-2025
    5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

    CHAPTER 6. GLOBAL LIPID DISORDER TREATMENT MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
    6.1. GLOBAL LIPID DISORDER TREATMENT MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
    6.1.1. Global Lipid Disorder Treatment Market Production (Volume) and Share (%) By Region, 2017-2025
    6.1.2. Global Lipid Disorder Treatment Market Consumption (Volume) and Share (%) By Region, 2017-2025
    6.1.3. North America Market Production and Consumption, 2017-2025
    6.1.4. Europe Market Production and Consumption, 2017-2025
    6.1.5. Asia Pacific Market Production and Consumption, 2017-2025
    6.1.6. South America Market Production and Consumption, 2017-2025
    6.1.7. Rest of the World Market Production and Consumption, 2017-2025

    CHAPTER 7. MARKET DETERMINANTS
    7.1. MARKET DRIVERS
    7.2. MARKET RESTRAINTS
    7.3. MARKET OPPORTUNITIES
    7.4. MARKET DETERMINANTS RADAR CHART

    CHAPTER 8. GLOBAL LIPID DISORDER TREATMENT MARKET COMPETITION BY MANUFACTURERS
    8.1. GLOBAL LIPID DISORDER TREATMENT PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
    8.1.1. Global Lipid Disorder Treatment Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
    8.2. GLOBAL LIPID DISORDER TREATMENT REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    8.2.1. Global Lipid Disorder Treatment Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
    8.3. LIPID DISORDER TREATMENT MARKET COMPETITIVE SITUATION AND TRENDS
    8.3.1. Lipid Disorder Treatment Market Share (%) of Top 3 Manufacturers
    8.3.2. Lipid Disorder Treatment Market Share (%) of Top 5 Manufacturers

    CHAPTER 9. GLOBAL LIPID DISORDER TREATMENT MANUFACTURERS ANALYSIS
    9.1. PFIZER, INC.
    9.1.1. Business Overview
    9.1.2. Company Basic Information
    9.1.3. Lipid Disorder Treatment Product Details
    9.1.4. Pfizer, Inc. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.2. NOVARTIS AG
    9.2.1. Business Overview
    9.2.2. Company Basic Information
    9.2.3. Lipid Disorder Treatment Product Details
    9.2.4. Novartis AG Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.3. ASTRAZENECA PLC.
    9.3.1. Business Overview
    9.3.2. Company Basic Information
    9.3.3. Lipid Disorder Treatment Product Details
    9.3.4. Astrazeneca Plc. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.4. MERCK & CO.
    9.4.1. Business Overview
    9.4.2. Company Basic Information
    9.4.3. Lipid Disorder Treatment Product Details
    9.4.4. Merck & Co. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.5. EMCURE PHARMACEUTICALS LTD.
    9.5.1. Business Overview
    9.5.2. Company Basic Information
    9.5.3. Lipid Disorder Treatment Product Details
    9.5.4. Emcure Pharmaceuticals Ltd. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.6. RANBAXY LABORATORIES LTD.
    9.6.1. Business Overview
    9.6.2. Company Basic Information
    9.6.3. Lipid Disorder Treatment Product Details
    9.6.4. Ranbaxy Laboratories Ltd. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.7. TEVA PHARMACEUTICALS
    9.7.1. Business Overview
    9.7.2. Company Basic Information
    9.7.3. Lipid Disorder Treatment Product Details
    9.7.4. Teva Pharmaceuticals Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.8. MYLAN PHARMACEUTICALS, INC.
    9.8.1. Business Overview
    9.8.2. Company Basic Information
    9.8.3. Lipid Disorder Treatment Product Details
    9.8.4. Mylan Pharmaceuticals, Inc. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.9. KOWA PHARMACEUTICALS AMERICA, INC.
    9.9.1. Business Overview
    9.9.2. Company Basic Information
    9.9.3. Lipid Disorder Treatment Product Details
    9.9.4. Kowa Pharmaceuticals America, Inc. Lipid Disorder Treatment Production, Revenue and Gross Margin
    9.10. GLENMARK PHARMACEUTICALS LTD.
    9.10.1. Business Overview
    9.10.2. Company Basic Information
    9.10.3. Lipid Disorder Treatment Product Details
    9.10.4. Glenmark Pharmaceuticals Ltd. Lipid Disorder Treatment Production, Revenue and Gross Margin

    CHAPTER 10. LIPID DISORDER TREATMENT MARKET VALUE CHAIN ANALYSIS
    10.1. LIPID DISORDER TREATMENT INDUSTRIAL CHAIN ANALYSIS
    10.2. LIPID DISORDER TREATMENT KEY RAW MATERIALS ANALYSIS
    10.2.1. Key Raw Materials
    10.2.2. Price Trend of Key Raw Materials
    10.2.3. Key Suppliers of Raw Materials
    10.3. CONSUMER ANALYSIS
    10.3.1. Consumer 1
    10.3.2. Consumer 2
    10.3.3. Consumer 3
    10.3.4. Consumer 4

    keyboard_arrow_up
  • • Pfizer, Inc.
    • Novartis AG
    • Astrazeneca Plc.
    • Merck & Co.
    • Emcure Pharmaceuticals Ltd.
    • Ranbaxy Laboratories Ltd.
    • Teva Pharmaceuticals
    • Mylan Pharmaceuticals, Inc.
    • Kowa Pharmaceuticals America, Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Sun Pharmaceuticals Industries Ltd.
    • Wockhardt Limited.

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Lipid Disorder Treatment Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Lipid Disorder Treatment Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS